Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infectious Diseases

Set Alert for Infectious Diseases

Coronavirus Update: Vir, WuXi Terminate COVID-19 Antibody Pact

Xevudy, which was part of the deal, has already seen restrictions on its use due to diminished efficacy against Omicron. Plus, Ocugen is back in the game as the FDA has released the clinical hold on its Phase II/III vaccine trial, while Pfizer/BioNTech release new booster shot data for Comirnaty in children aged 6 months-5 years.

Coronavirus COVID-19 Vaccines

Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria

Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round. 

Financing Innovation

Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine

The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.

Commercial Companies

Gilead’s Lenacapavir On The Move Again As FDA Lifts Clinical Hold

The long-acting HIV drug’s greatest potential is for pre-exposure prophylaxis, where it would compete against ViiV’s long-acting injectable Apretude.

Infectious Diseases Clinical Trials

AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio

The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.

Deals Infectious Diseases

Phathom’s First Approval Of Voquezna Expected To Lay Ground For Larger Indications

The Takeda spinout got FDA approval of its acid blocker as combination therapy for H. pylori infections, but the bigger opportunities await in erosive esophagitis and non-erosive reflux disorder.

Approvals Business Strategies

Pfizer On Paxlovid: "There's Still A Long Way To Go"

Access to the COVID-19 treatment is broadening, but Pfizer says there is still work to do when it comes to getting the antiviral to patients quickly.

Coronavirus COVID-19 Infectious Diseases

Pfizer’s Paxlovid Misses On Prevention, But Impact Limited

A Phase II/III trial testing Paxlovid as a preventative treatment for COVID-19 failed to show a statistically significant efficacy benefit.

Coronavirus COVID-19 Infectious Diseases

Gilead Sees HIV Business Return To Sales Growth As Oncology Gets Boost

The company said screening and diagnosis were still below pre-pandemic levels, but Biktarvy and Descovy brought HIV sales back into positive territory.

Sales & Earnings Companies

Straggler Novavax Still Hopes To Hit Paydirt With Combo Vaccine

The company announced early data for a combination vaccine against SARS-CoV-2 and influenza, which could provide a revenue opportunity of $2bn.

Coronavirus COVID-19 Vaccines

AlloVir Gains Third RMAT Designation For Antiviral T Cell Therapy

Gaining the special regulatory status in a prophylactic setting for posoleucel is the most significant yet for the T cell therapy developer.

Infectious Diseases Companies

Moderna COVID-19 Vaccine Data Bring Multivalent Vs. Monovalent Debate Into Focus

Phase II/III data for mRNA-1273.211 showed superiority against variants of concern to the original Spikevax, but Moderna’s top competitor has questioned the need for multivalent approaches.

Vaccines Coronavirus COVID-19
See All
UsernamePublicRestriction

Register